Revenue Growth and Top-Line Beat
Total revenue of $24.3 million in Q2 (up 8% year-over-year). Management noted they exceeded the top-line guidance communicated last quarter.
Strong Profitability and Margins
Adjusted EBITDA of $8.7 million, representing a 36% adjusted EBITDA margin. Total gross margin improved to 66% from 59% year-over-year; Software gross margin increased to 89% (from 81%).
Software and Services Growth
Software revenue grew 9% and comprised 60% of total revenue; Services revenue grew 8% and comprised 40% of total revenue.
Product Line Performance
Discovery (ADMET Predictor) revenue rose 19% for the quarter (6% trailing 12 months) and represented ~19% of software revenue. Development (GastroPlus, MonolixSuite) revenue rose 12% for the quarter (3% trailing 12 months) and represented ~78% of software revenue.
Healthy Commercial Metrics and Cross-Sell Opportunity
Ended quarter with 297 commercial clients, average revenue per client of $124,000, quarterly renewal rate of 91% (87% trailing 12 months). In fiscal 2025, among clients >$100k software revenue, 50% purchased 2 products, 23% purchased 3, and 15% purchased 4+ — indicating meaningful cross-sell upside.
Services Backlog and Project Activity
Total services projects during the quarter were 199; ending services backlog increased 18% to $24.0 million from $20.4 million a year ago, signaling a healthy services pipeline.
Strong Balance Sheet
Ended the quarter with $41.8 million in cash and short-term investments, no debt, and continued strong free cash flow to support growth and innovation.
Strategic AI Collaborations with Large Pharma
Announced strategic collaboration programs with three large pharmaceutical companies to advance AI workflows across the drug development lifecycle using core platforms (GastroPlus, MonolixSuite, ADMET Predictor, Thales). Company expects AI to enhance product value and long-term growth.
Improved Software Mix and Lower Amortization
Software contributed a larger share of revenue and benefited from lower software-related costs due to reduced amortization following a prior impairment, helping boost software gross margin.